Recent advances in the identification and management of inherited hyperoxalurias
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Recent advances in the identification and management of inherited hyperoxalurias
Authors
Keywords
Primary hyperoxaluria, Nephrolithiasis, Kidney stones, Genetic
Journal
Urolithiasis
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2018-12-10
DOI
10.1007/s00240-018-1093-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Whole exome sequencing frequently detects a monogenic cause in early onset nephrolithiasis and nephrocalcinosis
- (2018) Ankana Daga et al. KIDNEY INTERNATIONAL
- Crystal clear cerebral ultrasound images mimicking acute asphyxia in an infant with primary hyperoxaluria
- (2017) Giulia Ardemani et al. EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY
- Use of polymer conjugates for the intraperoxisomal delivery of engineered human alanine:glyoxylate aminotransferase as a protein therapy for primary hyperoxaluria type I
- (2017) Alessandro Roncador et al. Nanomedicine-Nanotechnology Biology and Medicine
- A randomised Phase II/III study to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria
- (2017) Dawn Milliner et al. Urolithiasis
- RNA Interference (RNAi)-Based Therapeutics: Delivering on the Promise?
- (2016) Maggie L. Bobbin et al. Annual Review of Pharmacology and Toxicology
- Metabolism of 13C5-hydroxyproline in mouse models of Primary Hyperoxaluria and its inhibition by RNAi therapeutics targeting liver glycolate oxidase and hydroxyproline dehydrogenase
- (2016) Xingsheng Li et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Progress in Understanding the Genetics of Calcium-Containing Nephrolithiasis
- (2016) John A. Sayer JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria
- (2016) Abigail Liebow et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- siRNA Therapeutics for Primary Hyperoxaluria: A Beginning
- (2016) Dawn S Milliner MOLECULAR THERAPY
- Inhibition of Glycolate Oxidase With Dicer-substrate siRNA Reduces Calcium Oxalate Deposition in a Mouse Model of Primary Hyperoxaluria Type 1
- (2016) Chaitali Dutta et al. MOLECULAR THERAPY
- Glycolate Oxidase Is a Safe and Efficient Target for Substrate Reduction Therapy in a Mouse Model of Primary Hyperoxaluria Type I
- (2016) Cristina Martin-Higueras et al. MOLECULAR THERAPY
- A randomised Phase I/II trial to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria
- (2016) Bernd Hoppe et al. PEDIATRIC NEPHROLOGY
- DETAILED CLINICAL PHENOTYPING OF OXALATE MACULOPATHY IN PRIMARY HYPEROXALURIA TYPE 1 AND REVIEW OF THE LITERATURE
- (2016) Thierry Derveaux et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- The role of intestinal oxalate transport in hyperoxaluria and the formation of kidney stones in animals and man
- (2016) Jonathan M. Whittamore et al. Urolithiasis
- Simultaneous analysis of urinary metabolites for preliminary identification of primary hyperoxaluria
- (2016) Oliver Clifford-Mobley et al. ANNALS OF CLINICAL BIOCHEMISTRY
- The Chaperoning Activity of Amino-oxyacetic Acid on Folding-Defective Variants of Human Alanine:Glyoxylate Aminotransferase Causing Primary Hyperoxaluria Type I
- (2015) Elisa Oppici et al. ACS Chemical Biology
- Helper-dependent adenoviral vectors for liver-directed gene therapy of primary hyperoxaluria type 1
- (2015) R Castello et al. GENE THERAPY
- Pyridoxamine and pyridoxal are more effective than pyridoxine in rescuing folding-defective variants of human alanine:glyoxylate aminotransferase causing primary hyperoxaluria type I
- (2015) Elisa Oppici et al. HUMAN MOLECULAR GENETICS
- Skin manifestations of primary hyperoxaluria: a case report
- (2015) Rony Shreberk-Hassidim et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- Phenotype-Genotype Correlations and Estimated Carrier Frequencies of Primary Hyperoxaluria
- (2015) K. Hopp et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Nephrocalcinosis is a risk factor for kidney failure in primary hyperoxaluria
- (2015) Xiaojing Tang et al. KIDNEY INTERNATIONAL
- Progressive polyradiculoneuropathy due to intraneural oxalate deposition in type 1 primary hyperoxaluria
- (2015) Sarah E. Berini et al. MUSCLE & NERVE
- Bone impairment in primary hyperoxaluria: a review
- (2015) Justine Bacchetta et al. PEDIATRIC NEPHROLOGY
- Surgical Management of Stone Disease in Patients With Primary Hyperoxaluria
- (2015) Alonso Carrasco et al. UROLOGY
- Sustained Pyridoxine Response in Primary Hyperoxaluria Type 1 Recipients of Kidney Alone Transplant
- (2014) E. C. Lorenz et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Vitamin B6 in Primary Hyperoxaluria I: First Prospective Trial after 40 Years of Practice
- (2014) H. Hoyer-Kuhn et al. Clinical Journal of the American Society of Nephrology
- Mutations inHAO1encoding glycolate oxidase cause isolated glycolic aciduria
- (2014) Yaacov Frishberg et al. JOURNAL OF MEDICAL GENETICS
- Fourteen Monogenic Genes Account for 15% of Nephrolithiasis/Nephrocalcinosis
- (2014) J. Halbritter et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Pharmacologic rescue of an enzyme-trafficking defect in primary hyperoxaluria 1
- (2014) Non Miyata et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Multiple mechanisms of action of pyridoxine in primary hyperoxaluria type 1
- (2013) Sonia Fargue et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- The chaperone role of the pyridoxal 5′-phosphate and its implications for rare diseases involving B6-dependent enzymes
- (2013) Barbara Cellini et al. CLINICAL BIOCHEMISTRY
- Extracorporal shock wave lithotripsy in the management of stones in children with oxalosis—still the first choice?
- (2013) Eslam Al-Abadi et al. PEDIATRIC NEPHROLOGY
- Hereditary causes of kidney stones and chronic kidney disease
- (2013) Vidar O. Edvardsson et al. PEDIATRIC NEPHROLOGY
- Inhibition of LDH-A by lentivirus-mediated small interfering RNA suppresses intestinal-type gastric cancer tumorigenicity through the downregulation of Oct4
- (2012) Yongjie Zhang et al. CANCER LETTERS
- The enzyme 4-hydroxy-2-oxoglutarate aldolase is deficient in primary hyperoxaluria type 3
- (2012) E. L. Williams et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment
- (2012) P. Cochat et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- LDH-A silencing suppresses breast cancer tumorigenicity through induction of oxidative stress mediated mitochondrial pathway apoptosis
- (2011) Zhi-Yu Wang et al. BREAST CANCER RESEARCH AND TREATMENT
- Primary Hyperoxaluria Type III Gene HOGA1 (Formerly DHDPSL) as a Possible Risk Factor for Idiopathic Calcium Oxalate Urolithiasis
- (2011) C. G. Monico et al. Clinical Journal of the American Society of Nephrology
- Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria
- (2011) B. Hoppe et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Mutations in DHDPSL Are Responsible For Primary Hyperoxaluria Type III
- (2010) Ruth Belostotsky et al. AMERICAN JOURNAL OF HUMAN GENETICS
- Enteric oxalate elimination is induced and oxalate is normalized in a mouse model of primary hyperoxaluria following intestinal colonization with Oxalobacter
- (2010) Marguerite Hatch et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Cardiac Abnormalities in Primary Hyperoxaluria
- (2010) Farouk Mookadam et al. CIRCULATION JOURNAL
- Genotype–phenotype correlation in primary hyperoxaluria type 1: the p.Gly170Arg AGXT mutation is associated with a better outcome
- (2009) Jérôme Harambat et al. KIDNEY INTERNATIONAL
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started